Oslo, Norway, May 3, 2021 - Vaccibody AS, a clinical-stage biopharmaceutical
company dedicated to the discovery and development of vaccines and novel
immunotherapies, announced that 800,000 share options have been granted to
Harald Gurvin in connection with his appointment as Chief Financial Officer. The
share options will have a strike price of NOK 76.77 per share, have a five-year
term and will vest equally over a four-year vesting period. After the award of
the share options, Harald Gurvin holds a total of 800,000 share options and 0
Please see further details in attached document.